TMCnet News
Downgrade Alert for Idenix Pharmaceuticals (IDIX)Jan 30, 2013 (SmarTrend(R) Upgrades/Downgrades via COMTEX) -- Idenix Pharmaceuticals (NASDAQ:IDIX) was downgraded from Outperform to Neutral at Wedbush today. The stock closed yesterday at $4.74 on volume of 1.1 million shares, below average daily volume of 1.2 million. Potential upside of 39.2% exists for Idenix Pharmaceuticals, based on a current level of $4.74 and analysts' average consensus price target of $6.60. The stock should find initial resistance at its 50-day moving average (MA) of $4.87 and further resistance at its 200-day MA of $6.74. Idenix Pharmaceuticals Inc. is a biopharmaceutical company that discovers and develops drugs for the treatment of human viral and other infectious diseases. The Company is focusing on the treatment of infections caused by hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV). Idenix Pharmaceuticals share prices have moved between a 52-week high of $15.25 and a 52-week low of $3.35 and closed yesterday at 41% above that low price at $4.74 per share. The 200-day and 50-day moving averages have moved 0.83% lower and 0.08% lower over the past week, respectively. SmarTrend is tracking the current trend status for Idenix Pharmaceuticals and will alert subscribers who have IDIX in their portfolio or watchlist when shares have changed trend direction. Write to Chip Brian at [email protected] --------------------------------------------------------------------------------------------- SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup |